Ketogenic diet has been
proposed for the adjuvant therapy in the treatment of brain tumors. The
rationale behind using ketogenic diet in the cancer treatment is the inability
of tumor mitochondria to oxidize KBs. Recent studies on ketone body metabolism
using 9L and RG2 cell lines and glioma models suggest that brain tumor
mitochondria are capable of oxidizing ketone bodies. The current study was undertaken
to determine relative utilization of betahydroxy-butyrate (BHB) and glucose in patient-derived
glioblastoma cells. Our findings clearly indicate that human brain tumor cells are fully capable of oxidizing ketone bodies even under
normoglycemic conditions.
This abstract and the presentation materials are available to members only; a login is required.